We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > izencitinib

News List

Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis drugs
August 24, 2021
Theravance Biopharma, Inc. today announced top-line results from its Phase 2b dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis.
J&J, Theravance's izencitinib fails Phase II ulcerative colitis trial firstwordpharma
August 24, 2021
Shares in Theravance Biopharma tumbled about 22% in after-hours trade on Monday after the company said izencitinib did not meet the primary endpoint of a Phase IIb trial of patients with ulcerative colitis (UC).
Theravance Biopharma Announces Proposed Public Offering of Ordinary Shares firstwordpharma
June 25, 2021
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), announced today that it intends to offer its ordinary shares in an underwritten public offering.
Theravance Biopharma Plans Upcoming Stock Sale; Shares Sink Nearly 10% in Extended Trading firstwordpharma
June 25, 2021
Shares of Theravance Biopharma were down almost 10% in after-hours trading on Thursday after the company disclosed plans for a public offering of its common stock, as reported by Fidelity.